Cancel

Psoriasis Prime Time: TYK Inhibition in Hard-to-Treat Psoriasis

Target Audience This activity has been designed to address the educational needs of dermatologists, dermatology nurse practitioners, and PAs. It may also be of benefit to primary care clinicians, rheumatologists, and other healthcare practitioners who are interested in the treatment of psoriasis. Program Overview In this edition of Psoriasis Prime Time, the faculty reviews the use of allosteric tyrosine kinase 2 (TYK2) inhibitors in the treatment of hard-to-treat psoriasis, including the ...
Paradigm Medical Communications, LLC.

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map